Duloxetine is the most recent drug from the pharmacological family of serotonin and
norepinephrine reuptake inhibitors approved with indication in major depressive disorder …

Rationale The optimal dose for achieving the maximum antidepressive effect of selective
serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenalin reuptake inhibitors (SNRIs) …

BACKGROUND: Pooled data from double-blind, placebo-controlled studies were utilized to
compare the safety and efficacy of duloxetine in the treatment of major depressive disorder …

BACKGROUND: Pain complaints commonly accompany major depressive disorder (MDD).
However, whether patients with MDD and pain complaints differ from those without pain …

Background: Duloxetine inhibits both serotonin and norepinephrine reuptake and is
marketed as a treatment for both the core emotional symptoms and painful physical …

Most patients with major depressive disorder (MDD) have symptoms of anxiety associated
with their depression. Duloxetine, a potent and balanced dual serotonin and norepinephrine …

Duloxetine has demonstrated efficacy for the treatment of major depressive disorder (MDD)
at a dose of 60 mg/day (given once daily). Whereas the target dose for the majority of …

Objective: To compare efficacy of remaining on duloxetine 60 mg to increasing to 120 mg qd
in patients without remission of major depressive disorder (MDD) after 6 weeks at 60 mg …

Objectives: This study aimed to compare pain‐related outcomes and health care utilization
among patients with major depressive disorder (MDD) treated with duloxetine versus other …

Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for
the treatment of major depressive disorder. In this analysis, data from eight, double-blind …